Research and Markets: Premenstrual Syndrome Pipeline Review, H1 2015 - Analysis of 4 Companies & 5 Drug Profiles

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/hzthzh/premenstrual) has announced the addition of the "Premenstrual Syndrome - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Premenstrual Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • DEKK-TEC, Inc.
  • M et P Pharma AG
  • Pherin Pharmaceuticals, Inc.
  • Umecrine Mood AB

Drug Profiles

  • PH-80PMD
  • progesterone
  • Small Molecule-1 to Antagonize GABAA Receptor for PMDD
  • Small Molecule-2 to Antagonize GABAA Receptor for PMDD
  • UC-1010

For more information visit http://www.researchandmarkets.com/research/hzthzh/premenstrual

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Women's Health